Almirall and Microsoft partner for dermatological drug development

01 Feb 2024
www.pharmaceutical-technology.com
Almirall and Microsoft partner for dermatological drug development
Preview
Source: Pharmaceutical Technology
The collaboration aims to expedite the development of new dermatological treatment options. Credit: Kmpzzz / Shutterstock.com.
Pharmaceutical company Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology.
The three-year collaboration will leverage generative artificial intelligence (genAI) and advanced analytics to enhance drug discovery and development processes, aiming to bring forward new treatments in medical dermatology.
Microsoft Industry Solutions, Microsoft partners and Almirall will establish a joint “digital office” which will build on the pharma company’s comprehensive data platform.
By combining Almirall’s research and development (R&D) and drug discovery capabilities with Microsoft’s digital technologies, the collaboration aims to expedite the development of new dermatological treatment options.
Almirall CEO Carlos Gallardo stated: “This agreement with Microsoft is a significant advancement in our digital transformation to achieve our goal of delivering novel treatment options for patients.
See Also:Takeda and Protagonist sign rusfertide development deal
Almirall and Microsoft partner for dermatological drug development
Preview
Source: Pharmaceutical Technology
Revolo advances plans to tackle eosinophilic esophagitis with orphan drug tag
Almirall and Microsoft partner for dermatological drug development
Preview
Source: Pharmaceutical Technology
“It will empower us to apply the latest technologies to transform our ways of working, and accelerate drug discovery.”
A significant aspect of the collaboration is the use of genAI for the quick analysis of large datasets, thereby establishing a digital, agile and patient-centric approach within Almirall’s R&D operations.
The goal is to expedite the discovery of new treatment targets and synthesisable molecules, enriching Almirall’s dermatology pipeline.
The alliance is set to streamline operations through data and AI, developing an intelligence-driven technology platform.
AI technologies will be used to select drug discovery projects, focusing on novelty and commercial potential prior to validation.
Microsoft Spain country general manager Alberto Granados stated: “Through this strategic partnership, Microsoft and its industry solutions organisation will collaborate with Almirall towards their goal of becoming the greatest dermatology company ever, revolutionising dermatological treatments and providing patients with the best possible solutions by leveraging Microsoft cutting-edge technologies of advanced analytics and generative artificial intelligence to foster innovation in drug discovery and development.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.